瑞银发表报告,列出最具潜力超市场预期收益((Buy rated HK listed stocks with highest UBSe earnings upside above consensus estimate)的港股买入名单:股份│瑞银与同业对企业今明两年综合盈测差异康希诺生物(06185.HK) +0.540 (+1.167%) 沽空 $2.27百万; 比率 3.129% │97%石药集团(01093.HK) +0.030 (+0.392%) 沽空 $4.46亿; 比率 25.679% │60%三生制药(01530.HK) +0.960 (+3.117%) 沽空 $1.48亿; 比率 6.463% │42%科济药业-B(02171.HK) +0.460 (+2.791%) 沽空 $4.38百万; 比率 40.673% │42%上石化(00338.HK) +0.020 (+1.504%) 沽空 $86.21万; 比率 8.751% │37%越秀地产(00123.HK) +0.060 (+1.339%) 沽空 $1.03千万; 比率 23.672% │35%金风科技(02208.HK) +0.210 (+1.591%) 沽空 $1.21千万; 比率 7.723% │33%科伦博泰生物-B(06990.HK) +7.800 (+1.741%) 沽空 $1.11亿; 比率 24.334% │27%中信建投证券(06066.HK) -0.240 (-1.822%) 沽空 $2.33千万; 比率 12.030% │26%恒瑞医药(01276.HK) -1.350 (-1.795%) 沽空 $1.15亿; 比率 25.001% │25%海丰国际(01308.HK) +1.080 (+3.774%) 沽空 $1.13千万; 比率 9.154% │23%药明康德(02359.HK) -4.400 (-4.052%) 沽空 $1.64亿; 比率 28.294% │22%(wl/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-10-31 16:25。)